Oncology Today with Dr Neil Love

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

The management of metastatic EGFR-mutated non-small cell lung cancer has shifted from osimertinib monotherapy to combination regimens, specifically chemotherapy plus osimertinib or amivantamab plus lazertinib. These combinations demonstrate superior progression-free and overall survival, particularly in high-risk subgr...

Endometrial Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

Treatment for HER2-positive metastatic breast cancer has evolved significantly, with modern therapies like T-DXd, tucatinib, and pertuzumab substantially extending overall survival. Professor Sibylle Loibl highlights that while complete responses remain rare—estimated at 5-10%—continuous anti-HER2 therapy and the strat...

For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress

Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review

Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

Localized hormone receptor-positive breast cancer management requires integrating emerging clinical trial data with established treatment protocols. Recent findings from the Lidera study demonstrate the efficacy of oral selective estrogen receptor degraders (SERDs) in the adjuvant setting, while long-term follow-up fro...

Endometrial Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women’s Cancer

Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft

Nonmetastatic non-small cell lung cancer management has shifted toward neoadjuvant chemoimmunotherapy, significantly improving pathologic complete response rates and overall survival. Clinical practice now emphasizes multidisciplinary staging and the integration of perioperative checkpoint inhibitors, particularly for ...

Endometrial Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women’s Cancer

Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Novel therapeutic strategies for non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma and mantle cell lymphoma, are transforming clinical management. Experts evaluate the integration of CD79b-targeted agents like Polatuzumab Vedotin and CD19-directed therapies, emphasizing their efficacy in relapsed setting...

Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Antibody-drug conjugates (ADCs) are transforming breast cancer management by offering targeted, sustained responses in both metastatic and early-stage settings. Clinical data demonstrate significant improvements in progression-free and overall survival for patients with triple-negative, HER2-positive, and endocrine-res...

Endometrial Cancer — An Interview with Dr Floor J Backes

For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress

Androgen Deprivation Therapy for Prostate Cancer — An Interview with Dr Rana R McKay

For Oncology Nurses: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from the 2026 Annual ONS Congress

Targeted Therapies for Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit

Targeted therapies for HER2, RET, ALK, and ROS1 mutations in non-small cell lung cancer are shifting clinical practice, particularly regarding the use of tyrosine kinase inhibitors (TKIs) in adjuvant settings. While osimertinib and alectinib have established roles, clinicians are increasingly extrapolating these approa...

HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit

Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit